35. Yao Q, Doan LX, Zhang R, Bharadwaj U, Li M, Chen C. Thymosin-alpha1 modulates dendritic cell differentiation and functional
maturation from human peripheral blood CD14+ monocytes. Immunol Lett. 2007;110(2):110–20.
36. Yao W, Zhu Q, Yuan Y, Qiao M, Zhang Y, Zhai Z. Thymosin alpha 1 improves severe acute pancreatitis in rats via regulation
of peripheral T cell number and cytokine serum level. J Gastroenterol Hepatol. 2007;22(11):1866–71.
37. Iijima N, Yanagawa Y, Onoe K. Role of early- or late-phase activation of p38 mitogen-activated protein kinase induced
by tumour necrosis factor-alpha or 2,4-dinitrochlorobenzene during maturation of murine dendritic cells. Immunol 2003;110(3):322–8.
38. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C. A critical role for p38 mitogen-activated protein kinase in the
maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol.
2001;166(6):3837–45.
39. Goldstein A, Goldstein A. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opinion Biological
Therapy 2009;9:593-6-8.
40. Tuthill C. Issues in pharmaceutical development of thymosin alpha 1 from preclinical studies through marketing. Annals
New York Acad Sci. 2007;1112:351–56.
41. Ershler W, Moore A, Hacker M, Ninomiya J, Naylor P, Goldstein A. Specific antibody synthesis in vitro. II. Age-associated
thymosin enhancement of antitetanus antibody synthesis. Immunopharmacology. 1984;8:69–77.
42. Crosnier J, Jungers P, Courouc AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebo-controlled trial of hepatitis
B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet 1981;1(8218):455–9.
43. Grob P, Binswanger U, Zaruba K, Joller-Jemelka H, Schmid M, Hacki W, et al. Immunogenicity of a hepatitis B subunit vaccine
in hemodialysis and in renal transplant recipients. Antiviral Research 1983;3:43–52.
44. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis.
Immunogenicity and efficacy. N Engl J Med. 1984;311(8):496–501.
45. Gravenstein S, Ershler WB, Drumaskin S, Schwab R, Weksler ME. Anti-influenza antibody response: augmentation in elderly
"non-responders" by thymosin alpha 1. Gerontologist. 1986;26:150A.
46. Gravenstein S, Duthie EH, Miller BA, Roecker E, Drinka P, Prathipati K, et al. Augmentation of influenza antibody response
in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J Ame Geriatric Soc. 1989;37:1–8.
47. McConnell L, Gravenstein S, Roecker E, Spencer S, Simon G, Ershler W. Augmentation of influenza antibody levels and reduction
in attack rates in elderly subjects by thymosin alpha 1. Gerontologist. 1989;29:188A.
48. Shen SY, Corteza QB, Josselson J, Gravenstein S, Ershler WB, Sadler JH, et al. Age-dependent enhancement of influenza
vaccine responses by thymosin in chronic hemodialysis patients. In: Goldstein AL, editor. Biomedical Advances in Aging. New
York: Plenum Press; 1990. pp. 523–30.
49. Shen S, Josselson J, McRoy C, Sadler J, Chretien P. Effect of thymosin alpha 1 on Heptavax-B vaccination among hemodialysis
patients. Kidney Int. 1987:31:217.
50. Shen S, Josselson J, McRoy C, Sadler J, Chretien P. Effects of thymosin alpha 1 on peripheral T-cell and Heptavax-B vaccination
in previously non-responsive hemodialysis patients. Hepatol. 1987;7(5):1120.
|
